Yusuke Koike
Overview
Explore the profile of Yusuke Koike including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shibata K, Iwatani K, Imai Y, Yoshihara K, Miyajima K, Fukuokaya W, et al.
In Vivo
. 2025 Feb;
39(2):824-833.
PMID: 40010955
Background/aim: The lung immune prognostic index (LIPI), which is determined by assessing the derived neutrophil-to-lymphocyte ratio in conjunction with the level of lactate dehydrogenase, predicts outcomes in various cancers. Its...
2.
Shimomura T, Mori K, Ito K, Yasue K, Matsukawa A, Fukuokaya W, et al.
Int Urol Nephrol
. 2024 Jun;
56(12):3719-3725.
PMID: 38913290
Purpose: Although docetaxel and ARSI are picked up as treatment options against chemo-naïve metastatic CRPC in clinical guidelines for prostate cancer, there is no clear evidence which agent should be...
3.
Kurokawa G, Mori K, Sasaki H, Nakano J, Takahashi Y, Iwatani K, et al.
Anticancer Res
. 2024 Feb;
44(2):679-686.
PMID: 38307559
Background/aim: To evaluate the effectiveness of magnetic resonance imaging/ultrasound (MRI-US)-guided fusion biopsy in the detection of clinically significant prostate cancer (CSPC) and analyze the clinical features of patients highly suspected...
4.
Shimomura T, Mori K, Yasue K, Matsukawa A, Fukuokaya W, Yanagisawa T, et al.
Int J Clin Oncol
. 2023 Dec;
29(2):213-221.
PMID: 38103156
Purpose: The androgen receptor axis-targeted (ARAT) agents abiraterone and enzalutamide have been introduced against castration-resistant prostate cancer (CRPC). However, determining which of these agents should be used first is a...
5.
Miyajima K, Sato S, Uchida N, Suzuki H, Iwatani K, Imai Y, et al.
Clin Genitourin Cancer
. 2023 Nov;
22(2):149-156.e1.
PMID: 38007354
Background: We compared oncological outcomes between prostate cancer (PCa) patients with and without intraductal carcinoma of the prostate (IDC-P) after high-dose-rate brachytherapy (HDR-BT) with external beam radiation therapy (EBRT). Methods:...
6.
Nakazono M, Urabe F, Iwatani K, Imai Y, Tashiro K, Honda M, et al.
Int J Urol
. 2023 Aug;
30(12):1147-1154.
PMID: 37650359
Objectives: We have analyzed the long-term follow-up data of patients with prostate cancer (PCa) who underwent high-dose-rate brachytherapy (HDR-BT) and external beam radiotherapy (EBRT) combined with long-term androgen deprivation therapy...
7.
Takahashi K, Urabe F, Suhara Y, Nakano J, Yoshihara K, Goto Y, et al.
Jpn J Clin Oncol
. 2023 Aug;
53(12):1208-1214.
PMID: 37647644
Background: Multiple studies have demonstrated the effectiveness of neoadjuvant chemotherapy and adjuvant chemotherapy in patients with upper tract urothelial carcinoma compared with surgery alone. However, no clinical trial has established...
8.
New liposome-radionuclide-chelate combination for tumor targeting and rapid healthy tissue clearance
Umeda I, Koike Y, Ogata M, Kaneko E, Hamamichi S, Uehara T, et al.
J Control Release
. 2023 Aug;
361:847-855.
PMID: 37543291
Radionuclide imaging and therapy are promising methods for controlling systemic cancers; however, their clinical application has been limited by excessive radionuclide accumulation in healthy tissues. To minimize radionuclide accumulation in...
9.
Miyajima K, Suzuki H, Urabe F, Iwatani K, Imai Y, Yasue K, et al.
Int J Clin Oncol
. 2023 Jul;
28(9):1200-1206.
PMID: 37432614
Background: To explore correlations between the clinical attributes of secondary bladder cancer and brachytherapy, we retrospectively reviewed our institutional database on patients with localized prostate cancer who underwent low-dose-rate brachytherapy...
10.
Suzuki H, Urabe F, Iwatani K, Miyajima K, Imai Y, Tashiro K, et al.
Anticancer Res
. 2023 Jun;
43(7):3135-3143.
PMID: 37352008
Background/aim: A recent clinical trial indicated the usefulness of local radiation therapy of the prostate in patients with low-volume metastatic prostate cancer. High-dose-rate brachytherapy (HDR-BT) is used mainly for high-risk,...